prulifloxacin has been researched along with levofloxacin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Gualco, L; Marchese, A; Schito, AM; Schito, GC | 1 |
| Esposito, S; Ianniello, F; Leone, S; Noviello, S | 1 |
| Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| De Vecchi, E; Drago, L; Mattina, R; Nicola, L | 1 |
| Barbounakis, E; Kofteridis, DP; Lionakis, S; Maraki, S; Ntaoukakis, M; Ntasis, E; Samonis, G | 1 |
| Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G | 1 |
| Blasi, F; Centanni, S; Del Vecchio, A; Dionisio, P; Rosignoli, MT; Schaberg, T | 1 |
| Blasi, F; Bonizzoni, E; Campanini, M; Casali, A; Colagrande, P; Giusti, M; Gussoni, G; Iori, I; Mazzone, A; Politi, C; Sgambato, F; Valerio, A | 1 |
4 trial(s) available for prulifloxacin and levofloxacin
| Article | Year |
|---|---|
Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Dioxolanes; Double-Blind Method; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Piperazines; Prospective Studies; Prostatitis; Quinolones | 2007 |
Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Disk Diffusion Antimicrobial Tests; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Piperazines; Respiratory Tract Infections; Treatment Outcome; Urinary Tract Infections; Young Adult | 2012 |
Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Topics: Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Dioxolanes; Double-Blind Method; Female; Fluoroquinolones; Follow-Up Studies; Forced Expiratory Volume; Humans; Levofloxacin; Male; Middle Aged; Piperazines; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Dioxolanes; Disease Progression; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Male; Piperazines; Pulmonary Disease, Chronic Obstructive; Recurrence; Retreatment; Single-Blind Method; Symptom Assessment; Symptom Flare Up; Treatment Failure | 2016 |
10 other study(ies) available for prulifloxacin and levofloxacin
| Article | Year |
|---|---|
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Hemolysin Proteins; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Ultraviolet Rays; Urinary Tract Infections | 2007 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus; Urinary Tract Infections | 2006 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Klebsiella; Klebsiella Infections; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Respiratory Tract Infections; Selection, Genetic; Urinary Tract Infections | 2010 |
Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Candida albicans; Dioxolanes; Feces; Fluoroquinolones; Gastrointestinal Tract; Levofloxacin; Male; Mice; Mice, Inbred ICR; Models, Animal; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Sodium Chloride | 2011 |